Core Insights - Adtalem Global Education reported strong fiscal Q4 2025 earnings, with revenue of $457.1 million exceeding analyst expectations of $440.93 million, and adjusted EPS of $1.66 surpassing the estimate of $1.53, indicating a positive performance driven by student enrollment growth and operational efficiency [1][2] Financial Performance - Revenue (GAAP) for Q4 2025 was $457.1 million, an increase of 11.5% year-over-year from $409.9 million [2] - Adjusted EPS (Non-GAAP) reached $1.66, reflecting a 21.2% increase from $1.37 in Q4 2024 [2] - Adjusted EBITDA (Non-GAAP) was $110.2 million, up 13.2% from $97.4 million in the previous year [2] - Free Cash Flow (Non-GAAP) amounted to $283.4 million, an 18.3% increase from $239.5 million [2] Business Overview - Adtalem is a leading provider of postsecondary education in the U.S., focusing on healthcare through institutions like Chamberlain University and Walden University [3] - The company aims to meet the growing demand for healthcare professionals while ensuring regulatory compliance and financial stability [3] Enrollment and Segment Dynamics - Total enrollment increased by 10.2% year-over-year to 91,780 students, with Walden University seeing a 15.0% rise [5] - Chamberlain University reported a 5.8% increase in enrollment, reaching 38,891 students, although its adjusted operating margin decreased from 24.2% to 19.4% [6] - The Medical and Veterinary segment experienced a 1.0% enrollment growth, with revenue up 4.7%, but faced capacity constraints [7] Operational Focus - The company is investing in technology and digital tools to enhance student engagement and retention, particularly at Walden University [10] - Chamberlain University launched a new brand campaign and expanded partnerships to increase nursing graduates [10] Regulatory Compliance - Regulatory compliance is a key focus, with constructive interactions with the U.S. Department of Education and no concerns regarding student aid funding [13] - Walden's Doctor of Social Work program received accreditation, enhancing the institution's reputation [13] Future Guidance - For fiscal 2026, Adtalem projects revenue between $1.90 billion and $1.94 billion, and adjusted EPS of $7.60 to $7.90, indicating growth of 6.0% to 8.5% in revenue and 14.0% to 18.5% in adjusted EPS [14] - Management anticipates a moderation in top-line growth due to strong prior-year gains and plans to continue investments in technology and program development [14] Investor Considerations - Key considerations for investors include the sustainability of enrollment growth, particularly in the Medical and Veterinary segment, and the impact of ongoing investments on operating margins [15] - Regulatory changes affecting access to federal student aid could also influence future performance [15]